Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-02-04
DOI
https://doi.org/10.3389/fonc.2026.1779304
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

Li Zhuang, Yuewen Li, Yiteng Liang, Yilin Chen et al.
Frontiers in Oncology
PARP inhibition in cancer therapy
article

Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

Li Zhuang, Yuewen Li, Yiteng Liang, Yilin Chen, Bingyan Qian, Ruiting Xu, Weifang Wang, Hongmei Li, Kunzhong Zhou
article en

Abstract

No abstract available for this paper.
Frontiers in OncologyVol. 16
Kunming Medical University (CN)
National Natural Science Foundation of China, Kunming Medical University
Good health and well-being
Openalex Percentile: Top 66%
PARP inhibition in cancer therapy
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance — Li Zhuang, Yuewen Li, et al. · Frontiers in Oncology (2026) | TGRS Research Map | TGRS